Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

There are currently four monoclonal antibodies available that are directed against TNF: infliximab, adalimumab, golimumab and certolizumab. All of these agents are efficacious in RA, with clinical ...

BAT2506 is a proposed biosimilar to Simponi® which is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. Binding of golimumab to TNF ...

BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha). Originator ...

Immunotherapy. 2012;4(11):1167-1179. Up to half the patients on anti-TNF-α therapies have inadequate responses. Substantial inter- and even intra-individual variations in the pharmacokinetics of ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...